260 related articles for article (PubMed ID: 35497874)
21. Therapeutic targeting of regulatory T cells in cancer.
Shan F; Somasundaram A; Bruno TC; Workman CJ; Vignali DAA
Trends Cancer; 2022 Nov; 8(11):944-961. PubMed ID: 35853825
[TBL] [Abstract][Full Text] [Related]
22. Small molecule inhibitors targeting regulatory T cells for cancer treatment.
García-Díaz N; Wei Q; Taskén K
Eur J Immunol; 2024 Feb; 54(2):e2350448. PubMed ID: 37937687
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
[TBL] [Abstract][Full Text] [Related]
25. miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancer.
Lv M; Xu Y; Tang R; Ren J; Shen S; Chen Y; Liu B; Hou Y; Wang T
Mol Cancer Ther; 2014 Dec; 13(12):3152-62. PubMed ID: 25349304
[TBL] [Abstract][Full Text] [Related]
26. Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC.
Song H; Liu S; Zhao Z; Sun W; Wei X; Ma X; Zhao P; Gao D
Int Immunopharmacol; 2017 Nov; 52():197-202. PubMed ID: 28941416
[TBL] [Abstract][Full Text] [Related]
27. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
28. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
30. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
31. Regulatory T cells in tumor immunity.
Nishikawa H; Sakaguchi S
Int J Cancer; 2010 Aug; 127(4):759-67. PubMed ID: 20518016
[TBL] [Abstract][Full Text] [Related]
32. Differentiation, regulation and function of regulatory T cells in non-lymphoid tissues and tumors.
Ni H; Chen Y
Int Immunopharmacol; 2023 Aug; 121():110429. PubMed ID: 37327512
[TBL] [Abstract][Full Text] [Related]
33. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
34. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
[TBL] [Abstract][Full Text] [Related]
35. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
36. Regulatory T cells and potential inmmunotherapeutic targets in lung cancer.
Zhang D; Chen Z; Wang DC; Wang X
Cancer Metastasis Rev; 2015 Jun; 34(2):277-90. PubMed ID: 25962964
[TBL] [Abstract][Full Text] [Related]
37. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
39. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
40. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.
Pan XD; Mao YQ; Zhu LJ; Li J; Xie Y; Wang L; Zhang GB
Chin Med J (Engl); 2012 Jun; 125(11):2004-11. PubMed ID: 22884069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
